Asset Details
Do you wish to reserve the book?
Bioavailability of a Novel, Water‐Soluble Vitamin E Formulation in Malabsorbing Patients
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Bioavailability of a Novel, Water‐Soluble Vitamin E Formulation in Malabsorbing Patients
Do you wish to request the book?
Bioavailability of a Novel, Water‐Soluble Vitamin E Formulation in Malabsorbing Patients
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Bioavailability of a Novel, Water‐Soluble Vitamin E Formulation in Malabsorbing Patients
2007
Overview
In cystic fibrosis (CF), pancreatic insufficiency and a diminished bile acid pool cause malabsorption of important nutrients and dietary components leading to deficiency, poor nutritional status, and oxidative stress. Of particular significance is the malabsorption of fat-soluble nutrients and antioxidants, which are important for normal immune and neurologic function. Patients with CF often are deficient in these compounds despite supplementation with the current standard of care therapy. The objective was to compare the pharmacokinetic profile of this water-soluble vitamin E formulation (Aqua-E) with an oil-based softgel formulation in a malabsorbing patient population. Patients with CF who had documented malabsorption were recruited for participation in this pharmacokinetic study. Patients who met inclusion and exclusion criteria discontinued vitamin E supplementation, except for that in a multivitamin, for 7 to 21 days before the day of dosing. Patients were randomized to a single dose of 20 ml of Aqua-E or three oil-based softgels, which contained equivalent amounts of tocopherols. Blood was drawn from patients at time 0, 2, 4, 8, 24, 48, and 168 hr and analyzed for tocopherols. Eight patients were enrolled in the study and randomized to Aqua-E or softgels. The primary outcome, the absorption of gamma-tocopherol in Aqua-E (AUC=115 micro g/ml(*)hr), was significantly greater than that of oil-based softgels (AUC=25.3 micro g/ml(*)hr; P=0.013). Total-tocopherols (alpha+gamma+delta) in Aqua-E (AUC=294 micro g/ml(*)hr) showed a strong trend toward increased absorption compared with that of oil-based softgels (AUC=117 micro g/ml(*)hr; P=0.09). In conclusion, this novel, water-soluble formulation showed a marked and statistically significant increase in absorption of gamma-tocopherol in malabsorbing patients with CF compared with an oil-based formulation.
Publisher
Springer,Springer Nature B.V
Subject
/ Adult
/ alpha-Tocopherol - pharmacokinetics
/ Antioxidants - pharmacokinetics
/ Biological and medical sciences
/ Child
/ Cystic Fibrosis - complications
/ gamma-Tocopherol - pharmacokinetics
/ Gastroenterology. Liver. Pancreas. Abdomen
/ Humans
/ Liver. Biliary tract. Portal circulation. Exocrine pancreas
/ Malabsorption Syndromes - etiology
/ Malabsorption Syndromes - metabolism
/ Miscellaneous hereditary metabolic disorders
/ Polyethylene Glycols - pharmacokinetics
/ Stomach. Duodenum. Small intestine. Colon. Rectum. Anus
/ Tocopherols - pharmacokinetics
/ Vitamin E - analogs & derivatives
